- Compounds Useful as Immunomodulators
-
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
- -
-
Paragraph 1160; 1161
(2015/11/03)
-
- SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN
-
Disclosed herein are small molecule heterocyclic inhibitors of sepiapterin reductase (SPR), and pro-drugs and pharmaceutically acceptable salts thereof. The Also featured are pharmaceutical compositions of the compounds and uses of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, and neuropathic pain)
- -
-
-
- COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY
-
Compounds of formula (I): wherein X, L1, R1, L2, R2, R3, and R4 are as defined herein, are useful in the treatment or prophylaxis of Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia.
- -
-
-
- NAPHTHYLACETIC ACIDS
-
The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
- -
-
Page/Page column 86-87
(2010/06/15)
-
- Discovery and structure - Activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors
-
Dipeptidyl peptidase IV (DPP4) inhibitors are emerging as a new class of therapeutic agents for the treatment of type 2 diabetes. They exert their beneficial effects by increasing the levels of active glucagon-like peptide-1 and glucose-dependent insulino
- Pei, Zhonghua,Li, Xiaofeng,Von Geldern, Thomas W.,Longenecker, Kenton,Pireh, Daisy,Stewart, Kent D.,Backes, Bradley J.,Lai, Chunqiu,Lubben, Thomas H.,Ballaron, Stephen J.,Beno, David W. A.,Kempf-Grote, Anita J.,Sham, Hing L.,Trevillyan, James M.
-
p. 1983 - 1987
(2008/02/04)
-
- SUBSTITUTED PYRIDINONES
-
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.
- -
-
-
- ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE DERIVATIVES
-
A compound of formula (I): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.
- -
-
Page/Page column 31
(2008/06/13)
-